AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04504760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo will be administered orally.
Study NCT04504760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2910
Description: Multiple ascending dose of ONO-2910 will be administered orally.
Study NCT04504760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo will be administered orally.
Study NCT04190095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motion Tracking in VR
Description: Participant will wear motion sensors and VR devices
Study NCT04190095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Interaction
Description: Participant will perform VR interaction task
Study NCT02669537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoPro Camera
Description: The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
Study NCT01197235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin-α
Description: Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
Study NCT01197235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: Infusion of isotonic saline will be performed 1 hour before angiography
Study NCT00538538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with subretinal lucentis
Description: A gas bubble will be placed in the eye after the gel has been removed.
Study NCT00538538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with subretinal lucentis
Description: These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
Study NCT01086475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
Study NCT01086475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
Study NCT02580344 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
Study NCT03331562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: pembrolizumab solution for infusion
Study NCT03331562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: pembrolizumab solution for infusion
Study NCT03331562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: Paricalcitol solution for injection
Study NCT03331562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline solution for injection
Study NCT04328285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Oral Tablets
Study NCT04328285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Hydroxychloroquine
Description: Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
Study NCT04328285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir and ritonavir
Description: LPV/r Oral Tablets
Study NCT04328285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LPV/r Tablets
Description: Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
Study NCT00167947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Study NCT00167947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Study NCT00167947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Study NCT00167947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Study NCT00167947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamune (Sirolimus)
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Study NCT00167947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune (Sirolimus)
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Study NCT00327808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-1020
Description: 600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
Study NCT00327808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: 400 mcg BID x 14 days then 800 mcg/day x 7 more days
Study NCT03402087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days
Study NCT03402087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT03402087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT00517062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth hormone (Genotropin)
Description: Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
Study NCT00517062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo self-injected once a day subcutaneously at bedtime.
Study NCT04093700 — intervention group
Intervention type: DEVICE
Intervention: SureLock All-Suture Anchor
Description: Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
Study NCT02289378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Oxaliplatin and 5-Fu
Description: To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
Study NCT03308851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocorticision
Description: The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
Study NCT03308851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteoperforation
Description: The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
Study NCT01173653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation
Description: Randomly introducing patients to a Department of Health program to help them quit smoking.
Study NCT01173653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
Study NCT00454233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM543
Description: Oral
Study NCT02400580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: The patients in the treatment arm will receive 1000mg of IV acetaminophen.
Study NCT02400580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patients in the placebo arm will receive normal saline.
Study NCT03246854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR112
Description: DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
Study NCT02746380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBAL
Description: Adalimumab
Study NCT02746380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Adalimumab
Study NCT00454233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral
Study NCT00454233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01697332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xe gas
Description: 800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
Study NCT02286102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPAT
Description: OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
Study NCT02286102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Constavac
Description: Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
Study NCT04400500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Approaches to differential diagnosis and risk stratification
Description: Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
Study NCT04184648 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: no intervention
Study NCT03547141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01
Description: injection of MBA-P01 into the muscle of each contralateral foot in equal doses
Study NCT03547141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: injection of BOTOX into the muscle of each contralateral foot in equal doses
Study NCT04735029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal gun
Description: Thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points.
Study NCT04735029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat pack
Description: A hydrocollator heat pack used to simulate traditional thermal therapy
Study NCT01917331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone/Formoterol/Glycopyrrolate
Description: Active drug tested
Study NCT01917331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone/Formoterol
Description: Active comparator
Study NCT02646904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Beclomethasone Dipropionate
Description: Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
Study NCT02646904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CERCHIO 10 mg/ml OS
Description: For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
Study NCT00954785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle brace
Description: Sports Stirrup ankle brace (Aircast)
Study NCT00954785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle brace
Description: Sports Stirrup ankle brace (Aircast)
Study NCT00954785 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ankle brace
Description: Sports Stirrup ankle brace (Aircast)
Study NCT00954785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac 50 mg tds
Description: In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
Study NCT00954785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg mane
Description: In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
Study NCT01965925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
Study NCT01965925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
Study NCT00636818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
Study NCT00167622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
Study NCT00167622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy and oxygen if needed
Description: oxygen will be delivered via facial mask whenever needed and physiotherapy
Study NCT01820910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
Study NCT04098380 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Bite
Description: the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
Study NCT04098380 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Larger bite
Description: the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
Study NCT03540095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: See arm description
Study NCT03540095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral Nerve Block
Description: See arm description
Study NCT03291327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Lozenges for Home use
Study NCT03291327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Lozenges for Home use
Study NCT04318392 — intervention group
Intervention type: OTHER
Intervention: Breath Analysis
Description: Breath analysis using the ReCIVA device will take place during each study visit.
Study NCT04318392 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Function Tests
Description: Full Pulmonary Function Tests will be performed at baseline and during each study visit if not performed as part of routine clinical care.
Study NCT04318392 — intervention group
Intervention type: OTHER
Intervention: Blood sampling and storage for genetic analysis
Description: Additional voluntary consent will be sought for blood sampling and storage for genetic analysis at baseline.
Study NCT04318392 — intervention group
Intervention type: OTHER
Intervention: Blood sampling and storage of plasma for metabolomic analysis
Description: Blood sampling and storage of plasma for metabolomic analysis will take place during each study visit.
Study NCT04318392 — intervention group
Intervention type: OTHER
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage will be performed at baseline on all participants undergoing investigation with bronchoscopy or EBUS as part of routine clinical care for investigation of suspected sarcoidosis.
Study NCT04318392 — intervention group
Intervention type: OTHER
Intervention: Sputum Culture
Description: Sputum will be collected during each study visit if the patient can spontaneously expectorate and will be sent for routine microbial analysis as well as metagenomic sequencing.
Study NCT04318392 — intervention group
Intervention type: OTHER
Intervention: Spirometry
Description: Spirometry will be performed on all healthy controls prior to enrolment into the study
Study NCT04342065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib capsules
Description: received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
Study NCT04342065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.
Study NCT04976465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Description: Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH
Study NCT04976465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Without Anticoagulation
Description: Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ
Study NCT03529487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: Oxymetazoline gel applied intra-analy
Study NCT03888625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ILM Peeling
Description: peeling with complete removal of the internal limiting membrane (ILM)
Study NCT03888625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inverted ILM Peeling
Description: the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
Study NCT03394950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butyphthalide combined with rtPA
Description: Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
Study NCT03394950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rtPA
Description: Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
Study NCT03659435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RID-TDS 9.5 mg/24 h
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
Study NCT03659435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon® 9.5 mg/24 h
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Study NCT03738956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment.
Study NCT01867554 — intervention group
Intervention type: GENETIC
Intervention: gene analysis
Description: gene analysis
Study NCT03299114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whirlpool
Study NCT03299114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whirlpool
Study NCT02014675 — intervention group
Intervention type: DEVICE
Intervention: SD01 ICD lead